Free Trial
→ Buffett, Gates and Bezos Dumping Stocks (From Banyan Hill Publishing) (Ad)tc pixel

ImmuPharma (LON:IMM) Shares Up 15.2% - Should You Buy?

Written by MarketBeat
Updated September 21, 2025
ImmuPharma logo with Medical background

Key Points

  • ImmuPharma shares surged by 15.2%, reaching a high of GBX 14 ($0.19) after trading 19,387,861 shares, significantly above the average volume.
  • The company has a market capitalization of £66.99 million and reported an earnings per share of GBX (0.38), with analysts projecting a yearly EPS of -339.0000022.
  • ImmuPharma specializes in developing peptide-based therapeutics, with its lead program, P140 (Lupuzor™), targeting autoimmune diseases like Lupus.
  • Five stocks we like better than ImmuPharma.

Shares of ImmuPharma plc (LON:IMM - Get Free Report) traded up 15.2% during trading on Thursday . The stock traded as high as GBX 14 ($0.19) and last traded at GBX 13.25 ($0.18). 19,387,861 shares changed hands during trading, an increase of 128% from the average session volume of 8,507,979 shares. The stock had previously closed at GBX 11.50 ($0.15).

ImmuPharma Price Performance

The firm has a market cap of £62.47 million, a P/E ratio of -1,404.49 and a beta of 1.53. The firm's 50-day moving average price is GBX 4.28 and its 200 day moving average price is GBX 3.27.

ImmuPharma (LON:IMM - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The company reported GBX (0.38) earnings per share for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. Analysts forecast that ImmuPharma plc will post -339.0000022 earnings per share for the current year.

ImmuPharma Company Profile

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Further Reading

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Best Nuclear Energy Stocks to Buy Cover
The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report
Like this article? Share it with a colleague.